FDG-PET in monitoring therapy of breast cancer

[1]  David A Mankoff,et al.  Evolving role of positron emission tomography in breast cancer imaging. , 2005, Seminars in nuclear medicine.

[2]  A. Alavi,et al.  Fluorodeoxyglucose-PET in the management of breast cancer. , 2004, Radiologic clinics of North America.

[3]  Claudio Landoni,et al.  PET/CT and breast cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  J. Talbot,et al.  [18F]FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Prof. Dr. Peter Oehr,et al.  PET and PET-CT in Oncology , 2003, Springer Berlin Heidelberg.

[6]  Robert B Livingston,et al.  Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  H. Biersack,et al.  Locally advanced breast cancer: is PET useful for monitoring primary chemotherapy? , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  Adriaan A. Lammertsma,et al.  Measuring [18F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  L. Kostakoglu,et al.  18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  D. Mankoff,et al.  Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. , 2002, Academic radiology.

[11]  Robert B Livingston,et al.  Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  H. Palmedo.  What can we expect from MDR breast cancer imaging with sestamibi? , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  Michael E. Phelps,et al.  Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  Rainer Linke,et al.  18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study , 2001, European Journal of Nuclear Medicine.

[15]  M. Welch,et al.  Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M Schwaiger,et al.  Quantitative assessment of tumor metabolism using FDG-PET imaging. , 2000, Nuclear medicine and biology.

[17]  P A Salvadori,et al.  Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. , 2000, Clinical breast cancer.

[18]  P F Sharp,et al.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Mankoff,et al.  Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]‐sestamibi scintimammography , 1999, Cancer.

[21]  H. Biersack,et al.  Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. , 1999, Hybridoma.

[22]  B. Leone,et al.  Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. , 1998, The cancer journal from Scientific American.

[23]  Jonson Sd,et al.  PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. , 1998 .

[24]  D. Wickerham,et al.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S Charrier,et al.  Clinical and pathological response to primary chemotherapy in operable breast cancer. , 1997, European journal of cancer.

[26]  H C Charles,et al.  Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  A. Buzdar,et al.  Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. , 1996, Cancer biotherapy & radiopharmaceuticals.

[28]  David J. Yang,et al.  Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  J E Husband,et al.  Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. , 1996, Radiology.

[30]  J. Bergh,et al.  Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. Teicher.  Hypoxia and drug resistance , 1994, Cancer and Metastasis Reviews.

[32]  R L Wahl,et al.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Aldrich,et al.  Tumour blood flow: measurement and manipulation for therapeutic gain. , 1993, Cancer treatment reviews.

[34]  G. van Kaick,et al.  Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  G. Hortobagyi,et al.  Treatment of locally advanced breast cancer. , 1992, Seminars in oncology.

[36]  A A Lammertsma,et al.  Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. , 1992, Cancer research.

[37]  M. Mintun,et al.  Positron Tomographic Assessment of 16α-[18F] Fluoro-17β-Estradiol Uptake in Metastatic Breast Carcinoma , 1991 .

[38]  K. Krohn,et al.  Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. , 1989, International journal of radiation oncology, biology, physics.

[39]  H. Minn,et al.  [18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer , 2004, European Journal of Nuclear Medicine.

[40]  V. Lowe.  PET and Radiotherapy , 2004 .

[41]  G. Antoch,et al.  PET/CT: Clinical Considerations , 2004 .

[42]  G. Cook,et al.  Nuclear Medicine Annual 2002 , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[43]  Michael J. Welch,et al.  Positron emission tomographic assessment of ”metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy , 1999, European Journal of Nuclear Medicine.